Literature DB >> 17579824

[Protection of renal function in diabetics].

C Hasslacher1.   

Abstract

The course of diabetic nephropathy is affected by several factors that can be manipulated. In primary prevention, near normal metabolic control beginning at the time of the diagnosis of diabetes diminishes the risk of microalbuminuria to an extent depending on the HbA1c level attained. Hypertensive diabetics should be consistently treated with renin-angiotensin system (RAS)-blocking agents. In secondary prevention, a multifactorial therapy is able to stop or retard further progression. Its components are a sustained decrease of blood pressure in the normotensive range using RAS-blocking agents (normotensive patients should also be treated) as well as near normal metabolic control that takes into account the changing pharmacokinetic and pharmacodynamic properties of blood glucose-lowering drugs in renal insufficiency. Consideration of further factors (smoking, protein intake, anemia) and several general nephroprotective measures complete the treatment spectrum. Therapy for dyslipidemia and the administration of aspirin are important in view of the high cardiovascular morbidity. It is essential to monitor kidney function and the therapeutic components at short intervals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579824     DOI: 10.1007/s00108-007-1894-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  45 in total

1.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.

Authors:  P Gaede; P Vedel; H H Parving; O Pedersen
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

2.  Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies.

Authors:  B Feldt-Rasmussen; E R Mathiesen; T Jensen; T Lauritzen; T Deckert
Journal:  Diabetologia       Date:  1991-03       Impact factor: 10.122

3.  A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes.

Authors:  L J Scott; J H Warram; L S Hanna; L M Laffel; L Ryan; A S Krolewski
Journal:  Diabetes       Date:  2001-12       Impact factor: 9.461

4.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

Authors:  John M Lachin; Saul Genuth; Patricia Cleary; Matthew D Davis; David M Nathan
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

5.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

6.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

7.  Serum lipids and the progression of nephropathy in type 1 diabetes.

Authors:  Merlin C Thomas; Milla Rosengård-Bärlund; Vashti Mills; Mats Rönnback; Stephen Thomas; Carol Forsblom; Mark E Cooper; Marja-Riitta Taskinen; Giancarlo Viberti; Per-Henrik Groop
Journal:  Diabetes Care       Date:  2006-02       Impact factor: 19.112

8.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients.

Authors:  K Rave; T Heise; A Pfützner; L Heinemann; P T Sawicki
Journal:  Diabetes Care       Date:  2001-05       Impact factor: 19.112

10.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.